The role of IDA scintigraphy in the follow-up of liver disease in patients with cystic fibrosis

Nuclear Medicine Communications

Volumn 23, Issue 7, 2002, Pages 673-681

  Foster, J A ^a   Ramsden, W H ^a   Conway, S P ^b   Taylor, J M ^b   Etherington, C ^b  

^a Regional Cystic Fibrosis Unit   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Cystic fibrosis; IDA scintigraphy; Liver disease

Indexed keywords

DIGLYCINE; DISOFENIN; MEBROFENIN; TAURINE; TECHNETIUM 99M; URSODEOXYCHOLIC ACID;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL EXAMINATION; CYSTIC FIBROSIS; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FOLLOW UP; HEPATOBILIARY SYSTEM; HUMAN; LIVER DISEASE; LIVER FUNCTION TEST; MALE; SCINTIGRAPHY; ULTRASOUND;

EID: 0036305014     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200207000-00012     Document Type: Article

References (27)

1. Cohn JA, Strong TV, Picciotto MR, Nairn AC, Collins FS, Fitz JG. Localization of the cystic fibrosis transmembrane conductance regulator in human bile duct epithelial cells. Gastroenterology 1993; 105: 1857-1864.
2. Scott-Jupp R, Lama M, Tanner MS. Prevalence of liver disease in cystic fibrosis. Arch Dis Child 1991; 66: 698-701.
3. Colombo C, Apostolo MG, Ferrari M, et al. Analysis of risk factors for the development of liver disease associated with cystic fibrosis. J Pediatr 1994; 124: 393-399.
4. Colombo C, Battezzati PM, Podda M. Hepatobiliary disease in cystic fibrosis. Semin Liver Dis 1994; 14: 259-269.
5. Colombo C, Battezzati PM, Strazzabosco M, Podda M. Liver and biliary problems in cystic fibrosis. Semin Liver Dis 1998; 18: 227-235.
6. Nagel RA, Westaby D, Javaid A, et al. Liver disease and bile duct abnormalities in adults with cystic fibrosis. Lancet 1989; 2: 1422-1425.
7. Colombo C, Battezzati PM, Podda M, Betsinardi N, Giunta A. Ursodeoxycholic acid for liver disease associated with cystic fibrosis. A double-blind multicentre trial. Hepatology 1996; 23: 1484-1490.
8. Strandvik B, Lindblad A. Cystic fibrosis. Is treatment with ursodeoxycholic acid of value? Scand J Gastroenterol 1994; 204(Suppl.): 65-67.
9. Lindblad A, Glaumann H, Strandvik B. A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease. Hepatology 1998; 27: 166-174.
10. Colombo C, Castellani MR, Balistreri WF, Seregni E, Assaisso ML, Giunta A. Scintigraphic documentation of an improvement in hepatobiliary excretory function after treatment with ursodeoxycholic acid in patients with cystic fibrosis and associated liver disease. Hepatology 1992; 15: 677-684.
11. Revell SD, Noble-Jamieson G, Robertson NRC, Barnes ND. Liver transplantation in cystic fibrosis. J R Soc Med 1993; 86: 111-112.
12. O'Connor PJ, Southern KW, Bowler IM, Irving HC, Robinson PJ, Littlewood JM. The role of hepatobiliary scintigraphy in cystic fibrosis. Hepatology 1996; 23: 281-287.
13. Colombo C, Crosignani A, Assaisso ML, et al. Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: A dose-response study. Hepatology 1992; 16: 924-930.
14. th edn. Liverpool, England. Royal Liverpool Children's NHS Trust, 1994: p. 6.
15. Roca I, Ciofetta G. Hepatobiliary scintigraphy in current pediatric practice. Q J Nucl Med 1998; 42: 113-118.
16. Dogan AS, Conway JJ, Lloyd-Still JD. Hepatobiliary scintigraphy in children with cystic fibrosis and liver disease. J Nucl Med 1994; 35: 432-435.
17. Wilson-Sharp RC, Irving HC, Brown RC, Chalmers DM, Littlewood JM. Ultrasonography of the pancreas, liver and biliary system in cystic fibrosis. Arch Dis Child 1984; 59: 923-926.
18. Willi UV, Reddish JM, Teele RL. Cystic fibrosis: its characteristic appearance on abdominal sonography. AJR 1980; 134: 1005-1010.
19. Quillin KP, Siegel MJ, Rothbaum R. Hepatobiliary sonography in cystic fibrosis. Pediatr Radiol 1993; 23: 533-535.
20. Graham N, Manhire AR, Stead RJ, Lees WR, Hodson ME, Batten JC. Cystic fibrosis: ultrasonographic findings in the pancreas and hepatobiliary system correlated with clinical data and pathology. Clin Radiol 1985; 36: 199-203.
21. Clayton BE, Jenkins P, Round JM. Paediatric chemical pathology: Clinical tests and reference ranges. London, England: Blackwell, 1980: 27-28.
22. Tanner MS, Taylor CJ. Liver disease in cystic fibrosis. Arch Dis Child 1995; 72: 281-284.
23. Shwachman H, Kulczycki LL. Long term study of one hundred and five patients with cystic fibrosis. Am J Dis Child 1958; 96: 6-15.
24. Colombo C, Setchell KD, Podda M, et al. Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis. J Pediatr 1990; 117: 482-489.
25. Cotting J, Lentze MJ, Reichen J. Effects of ursodeoxycholic acid treatment on nutrition and liver function in patients with cystic fibrosis and longstanding cholestasis. Gut 1990; 31: 918-921.
26. Gaskin KJ, Waters DLM, Howman-Giles R, et al. Liver disease and common bile duct stenosis in cystic fibrosis. N Engl J Med 1988; 318: 340-346.
27. Kowdley KV. Ursodeoxycholic acid therapy in hepatobiliary disease. Am J Med 2000; 108: 481-486.